Ziconotide
drugOn this page
Also known as .omega.-conotoxin m viiaSNX-111Ziconotidaomega-Conotoxin
Summary
Ziconotide (CHEMBL4594214) is an approved protein (ATC N02BG08) targeting CACNA1A and CACNA1B; indicated across 2 conditions.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: N02BG08
- Targets: 2 (CACNA1A, CACNA1B)
- Indications: 2 conditions
- Clinical trials: 10
- Chemistry: 2639.2 Da · C102H172N36O32S7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594214 |
| Name | Ziconotide |
| Type | Protein |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 16135415 |
| ATC | N02BG08 |
| Molecular formula | C102H172N36O32S7 |
| Molecular weight | 2639.2 |
| InChIKey | BPKIMPVREBSLAJ-QTBYCLKRSA-N |
SMILES: C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
IUPAC name: 2-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,54S,60S,63R,68R,71S,77S)-63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-[(1R)-1-hydroxyethyl]-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid
Also known as: .omega.-conotoxin m viia, SNX-111, Ziconotida, Ziconotide, omega-Conotoxin, ZICONOTIDE
Patent coverage: 545 distinct patent families (1,201 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,058 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CACNA1A | Cav2.1 | Antagonist | 6.3 | 0% | O00555 |
| CACNA1B | Cav2.2 | Antagonist | 1 | 0.3% | Q00975 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Voltage-dependent N-type calcium channel subunit alpha-1B.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CACNA1B | 6.3 | IC50 | 500 | nM | CHEMBL_ACT_1476708 |
| CACNA1B | 6.22 | IC50 | 600 | nM | CHEMBL_ACT_1476707 |
Target pathways
Aggregated over 2 target gene(s): CACNA1A, CACNA1B.
Top Reactome pathways
6 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Presynaptic depolarization and calcium channel opening | 2 | CACNA1A, CACNA1B |
| Transmission across Chemical Synapses | 2 | CACNA1A, CACNA1B |
| Neuronal System | 2 | CACNA1A, CACNA1B |
| Metabolism | 1 | CACNA1A |
| Integration of energy metabolism | 1 | CACNA1A |
| Regulation of insulin secretion | 1 | CACNA1A |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| chemical synaptic transmission | 2 |
| modulation of chemical synaptic transmission | 2 |
| calcium ion transmembrane transport | 2 |
| calcium ion import across plasma membrane | 2 |
| response to amyloid-beta | 2 |
| monoatomic ion transport | 2 |
| calcium ion transport | 2 |
| monoatomic ion transmembrane transport | 2 |
| transmembrane transport | 2 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| cellular response to amyloid-beta | 1 |
| positive regulation of calcium ion-dependent exocytosis of neurotransmitter | 1 |
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4).
The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE4 | 3 |
| PHASE2 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01373983 | PHASE4 | COMPLETED | Intrathecal Bolus Doses of Ziconotide |
| NCT01992562 | PHASE4 | WITHDRAWN | Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy |
| NCT03321955 | PHASE4 | COMPLETED | Ziconotide as First-Line IDT |
| NCT00076544 | PHASE3 | COMPLETED | Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain |
| NCT00002160 | PHASE2 | COMPLETED | A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain |
| NCT00996983 | PHASE2 | UNKNOWN | Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer |
| NCT04321408 | Not specified | RECRUITING | OP2C : Prialt® Observatory in Clinical Practice |
| NCT06541184 | Not specified | RECRUITING | Ziconotide for Non-cancer Pain by Intrathecal Administration |
| NCT07499882 | Not specified | NOT_YET_RECRUITING | Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy |
| NCT01888120 | Not specified | COMPLETED | Patient Registry of Intrathecal Ziconotide Management(PRIZM) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
25 molecules share ≥1 primary target. Top 25 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Nifedipine | ChEMBL + PubChem | Phase 4 (approved) | CACNA1A, CACNA1B |
| NIMODIPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1A, CACNA1B |
| TACRINE | ChEMBL | Phase 4 (approved) | CACNA1A, CACNA1B |
| AMITRIPTYLINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| AMOXAPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| CLOMIPRAMINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| CYCLOBENZAPRINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| DESIPRAMINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| IMIPRAMINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1B |
| MAPROTILINE | ChEMBL | Phase 4 (approved) | CACNA1B |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | CACNA1B |
| NORTRIPTYLINE | ChEMBL | Phase 4 (approved) | CACNA1B |
| PROMETHAZINE | ChEMBL | Phase 4 (approved) | CACNA1B |
| PROTRIPTYLINE | ChEMBL | Phase 4 (approved) | CACNA1B |
| TRIMIPRAMINE | ChEMBL | Phase 4 (approved) | CACNA1B |
| CILNIDIPINE | ChEMBL | Phase 3 | CACNA1B |
| HESPERIDIN | ChEMBL | Phase 3 | CACNA1B |
| OPIPRAMOL | ChEMBL | Phase 3 | CACNA1B |
| FLUNARIZINE | ChEMBL | Phase 2 | CACNA1B |
| LOMERIZINE | ChEMBL | Phase 2 | CACNA1B |
| SELICICLIB | ChEMBL | Phase 2 | CACNA1B |
| Z160 | ChEMBL | Phase 2 | CACNA1B |
| Clotrimazole | PubChem | Approved | CACNA1B |
| Econazole | PubChem | Approved | CACNA1B |
| Miconazole | PubChem | Approved | CACNA1B |